MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
12.18
-0.12 (-0.98%)
Sep 25, 2026, 4:00 PM EDT - Market closed
MiNK Therapeutics Employees
MiNK Therapeutics had 15 employees as of December 31, 2025. The number of employees decreased by 8 or -34.78% compared to the previous year.
Employees
15
Change (1Y)
-8
Growth (1Y)
-34.78%
Revenue / Employee
n/a
Profits / Employee
-$757,359
Market Cap
62.15M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | -8 | -34.78% |
| Dec 31, 2024 | 23 | -8 | -25.81% |
| Dec 31, 2023 | 31 | -6 | -16.22% |
| Dec 31, 2022 | 37 | 4 | 12.12% |
| Dec 31, 2021 | 33 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Alps Group | 93 |
| XBiotech | 87 |
| Clene | 79 |
| MindWalk Holdings | 77 |
| Xilio Therapeutics | 76 |
| Mereo BioPharma Group | 39 |
| Boundless Bio | 28 |
| Alterity Therapeutics | 11 |
INKT News
- 6 weeks ago - MiNK Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 6 weeks ago - MiNK Therapeutics Earnings release: Q2 2026 - Filings
- 6 weeks ago - MiNK Therapeutics Quarterly report: Q2 2026 - Filings
- 6 weeks ago - MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury - GlobeNewsWire
- 7 weeks ago - MiNK Therapeutics presents early observations from Phase 2 agenT-797 trial - TheFly
- 7 weeks ago - MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates - GlobeNewsWire
- 3 months ago - MiNK Therapeutics Transcript: AGM 2026 - Transcripts
- 3 months ago - MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting - GlobeNewsWire